Form 4: FibroGen CFO Sells Shares for Tax Obligation

FibroGen's Chief Financial Officer, David DeLucia, disposed of 52 shares of common stock to cover tax liabilities from vested restricted stock units.

Summary

• David DeLucia, Chief Financial Officer of FibroGen Inc. (FGEN), reported a transaction on December 6, 2025.
• The transaction involved the disposition of 52 shares of FibroGen Common Stock.
• The shares were withheld by the issuer to satisfy a tax obligation incurred by Mr. DeLucia upon the vesting of restricted stock units.
• The price per share for the disposed securities was $8.42.
• Following this transaction, Mr. DeLucia directly beneficially owns 4,489 shares of Common Stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax withholding, which is a neutral event and does not indicate positive or negative sentiment regarding the company's performance or outlook.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

This is a routine insider transaction related to executive compensation and tax compliance, which is common across all industries for publicly traded companies. It does not provide specific insights into broader industry trends for the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• The disposition of shares to cover tax obligations upon the vesting of restricted stock units is a standard practice for executive compensation in publicly traded companies, aligning with typical industry compensation structures.

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Minimal impact due to the small number of shares involved in a routine tax-related transaction.
• Employees: No direct impact on general employees.

Next Steps

• NA

Key Dates

Keywords

FibroGen, FGEN, Form 4, insider transaction, tax withholding, restricted stock units, CFO, equity compensation